The UK scientists and crew of the James Cook are deploying the ISIS again right now.
But a Genzyme-Isis tie up to distribute mipomersen makes a great deal of sense.
It will also receive two of Isis' diabetes drug candidates and do initial evaluations in humans.
Symphony investors also get a five-year warrant to purchase 4.25 million shares of Isis stock.
Isis Pharmaceuticals has had more false starts at the big time than just about any biotech.
The medicine, a once-a-week injection from Isis Pharmaceuticals, will finish midstage trials any day.
Isis even inked a marketing partnership with Genzyme, which is now part of Sanofi.
Isis and Lilly now are testing the drug on 600 patients in final-phase trials.
Just don't expect a one-for-one recreation of systems like Google Wallet or Isis.
ENGADGET: LevelUp unveils payment docks that take both NFC and QR codes, leave out the guesswork
Isis was initially stuck placing orders that exceeded demand, since the fabric was sold in bulk lots.
And Ms. Able reports that Cleo's sister, Treasures Biscay's Sapphire, aka Isis, is due in early June.
Thursday, Isis announced trials that could get mipomersen approved in the rare genetic disease familial hypercholesterolemia (FH).
Forbes.com reported last November that the two companies were in negotiations (see "Genzyme Eyes Isis Drug").
Isis Pharmaceuticals of Carlsbad, California, has launched another new class which it hopes will be equally successful.
One big disadvantage of Isis' drugs is that they collect in the liver, potentially causing side effects.
At first, Isis will get 30% of these profits, but as worldwide sales increase, so will Isis' take.
In 1999 came another setback, when Novartis halted work on Isis' lung cancer drug, then in early-stage trials.
The payments landscape is evolving with the entry of online channels like PayPal, Google wallet and Isis.
FORBES: Even Factoring In Big Growth Visa Looks Full At $150
There's no guarantee that just because Genzyme is looking at Isis that it will come through with a deal.
But Isis would offer Genzyme a bigger opportunity: a chance to launch a drug into a far broader market.
Isis landed its first deal in 1990, with Ciba-Geigy (now part of Novartis), to develop a lung cancer drug.
When Isis' antisense strand latched on there, it activated an enzyme that destroys the RNA that codes for PKC-alpha.
Google Wallet, which is active across the U.S., and Isis, which will launch in 2012, are based on NFC.
FORBES: Intuit: Mobile Payment 'Swipes' Will Go Away, But NFC Probably Not The Solution
Isis weighed in on average three-and-a-half pounds heavier than their Cambridge rivals Goldie.
Isis Pharmaceuticals has signed a deal with Bristol-Myers Squibb for a cholesterol drug that is not yet in clinical trials.
Isis shares are down 40% over two years, and trade at a third of what they did in early 2002.
Only in the last week did the Syrian regime intensify strikes on Raqqa, a city in Syria's interior that is considered ISIS's headquarters.
The medicine, invented by Isis Pharmaceuticals, will be marketed by Genzyme, the rare-disease specialty unit of Sanofi, the French drug giant.
FORBES: After 24 Years Of Struggle, Has Stan Crooke Finally Birthed An Age Of Antisense?
Scientists from all over the globe come to the facility, known as Isis, to probe the structure and dynamics of matter.
One reason Isis needs money is the company plans to launch a study next year in patients with garden-variety high cholesterol.
应用推荐